NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $7.91 +0.38 (+5.03%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Capricor Therapeutics Stock (NASDAQ:CAPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$7.48▼$8.3450-Day Range$5.74▼$11.2252-Week Range$2.96▼$40.37Volume3.53 million shsAverage Volume3.26 million shsMarket Capitalization$459.85 millionP/E RatioN/ADividend YieldN/APrice Target$30.09Consensus RatingHold Company Overview Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications. The company is headquartered in San Diego, California, and its chief executive officer is Linda Marbán.AI Generated. May Contain Errors. Read More Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCAPR MarketRank™: 3.06624518966 of 5 starsCapricor Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 306th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingCapricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialCapricor Therapeutics has a consensus price target of $30.09, representing about 299.6% upside from its current price of $7.53.Amount of Analyst CoverageCapricor Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($2.39) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted35.55% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 7.38.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 5.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.09 News SentimentCapricor Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Capricor Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 19 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat Follows9 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.20% of the stock of Capricor Therapeutics is held by insiders.Percentage Held by Institutions21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Stock News HeadlinesCapricor, Regenxbio among gainers as White House pulls Trump’s FDA pickNovember 18 at 1:53 PM | msn.comCapricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy DeramiocelNovember 18 at 9:00 AM | benzinga.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 20 at 1:00 AM | Profits Run (Ad)Capricor Stock Rises: What's Going On?November 17 at 11:02 AM | benzinga.comFDA decision watch: Capricor’s DMD therapy faces make-or-break decision, Savara’s lung disease drug in the spotlight this weekNovember 16, 2026 | msn.comHC Wainwright Has Pessimistic View of CAPR FY2026 EarningsNovember 15, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)November 15, 2026 | theglobeandmail.comCapricor Therapeutics (NASDAQ:CAPR) Upgraded at JonesTradingNovember 14, 2026 | americanbankingnews.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $28.86 at the beginning of 2026. Since then, CAPR shares have decreased by 73.9% and is now trading at $7.53. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) posted its quarterly earnings data on Tuesday, November, 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.29. Read the conference call transcript. Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' top institutional investors include State Street Corp (5.19%), RA Capital Management L.P. (5.18%), Soleus Capital Management L.P. (1.20%) and Goldman Sachs Group Inc. (1.20%). Insiders that own company stock include Shinyaku Co Ltd Nippon, Anthony Bergmann and Karimah Es Sabar. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Tesla (TSLA), Alibaba Group (BABA), Vaxart (VXRT) and Micron Technology (MU). Company Calendar Last Earnings11/10/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CAPR's financial health is in the Green zone, according to TradeSmith. CAPR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075Employees231Year Founded2005Price Target and Rating Average Price Target for Capricor Therapeutics$30.09 High Price Target$60.00 Low Price Target$2.00 Potential Upside/Downside+291.7%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.71% Return on Assets-42.71% Debt Debt-to-Equity RatioN/A Current Ratio6.77 Quick Ratio6.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.61 per share Price / Book2.13Miscellaneous Outstanding Shares58,142,000Free Float52,793,000Market Cap$446.70 million OptionableOptionable Beta0.80 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:CAPR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.